PepTrackevidence-graded reference
NAD+ (and precursors NMN/NR)
fig.1 — stylized molecular motif · not a true peptide
Longevity

NAD+ (and precursors NMN/NR)

nicotinamide adenine dinucleotide · NMN · NR · not a peptide (coenzyme)

Flagship longevity product, celebrity-driven; ubiquitous on peptide-clinic menus (so users expect it) - but NOT a peptide.

Evidence
Emechanistic / anecdotal
Status
Research-use-only — gray marketas of 2026-06
Approval
Not approved
Category
Longevity
Route
Oral · Subcutaneous · IV
Demand rank
honorable mention
01Dosing & Protocol
Typical · reference only
Oral NMN 250-900 mg/day or NR 300-1000 mg/day (best-evidenced); injectable SC <=100 mg/injection (<=300 mg/week), IV 250-500 mg/session
Titration
Injectable: start low, slow infusion (rate-dependent AEs)
Reconstitution — illustrative, not a recommendation
Compounded SC: 500 mg vial + 2.5 mL BAC = 200 mg/mL; 100 mg = 50 U on U-100.
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial.
02Regulatory Status
Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Injectable NAD+ has a live FDA safety problem (2025 Class I recall, endotoxin). NMN reinstated as a supplement Sept 2025 (NDI required).
Status
Research-use-only — gray market
503A bulks
Not on the bulks list
Category 2
Coenzyme on a separate track (NOT in the peptide reclassification). NAD+ is 503B-INELIGIBLE (GenoGenix warning letter).
PCAC review
none scheduled
WADA
Not listed
03Evidence — the honest read
What the evidence actually shows

Oral precursors (NMN/NR) reliably raise blood NAD+ (surrogate) but functional benefit unproven; injectable NAD+ is poorly tolerated and not clearly superior. No FDA approval any route.

04Safety
Contraindications
  • Pregnancy/breastfeedinghard stop
  • Active/late-stage cancer (theoretical fuel; pause before chemo/surgery)
  • Endotoxin/sepsis vulnerability (injectable)
Key interactions
  • Antidiabetics (glucose effects - monitor)
  • Antihypertensives (additive BP - theoretical)
Serious signals
  • 2025 Class I recall of compounded injectable NAD+ (endotoxin -> ER visits)
  • IV 500 mg: ~100% moderate-to-severe acute AEs
  • 503B-ineligible
Monitoring
Glucose with antidiabetics; LFTs with high-dose oral.
05Related in Longevity
Epitalon (Epithalon)
mechanistic / anecdotal
grade E →
06Sources
1FDA GenoGenix recall; Frontiers in Aging 2026
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: moderate-good
← All peptides
Longevity

NAD+ (and precursors NMN/NR)

nicotinamide adenine dinucleotide · NMN · NR · not a true peptide (coenzyme)

Flagship longevity product, celebrity-driven; ubiquitous on peptide-clinic menus (so users expect it) - but NOT a peptide.

Evidence
E
mechanistic / anecdotal
Status
Research-use-only — gray market
as of 2026-06
FDA approval
Not approved
off-label / gray
Route
Oral · Subcutaneous · IV
Clinic protocol
Demand
—
honorable mention
WADA
Not listed
sport-legal
01

Dosing & protocol

Clinic protocol. Clinic-protocol / off-label extrapolation — not an FDA-approved regimen.
Typical — reference only

Oral NMN 250-900 mg/day or NR 300-1000 mg/day (best-evidenced); injectable SC <=100 mg/injection (<=300 mg/week), IV 250-500 mg/session

Worked reconstitution example

Compounded SC: 500 mg vial + 2.5 mL BAC = 200 mg/mL; 100 mg = 50 U on U-100.

Titration

Injectable: start low, slow infusion (rate-dependent AEs)

Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial (use the calculator →).
02

Regulatory status

Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Injectable NAD+ has a live FDA safety problem (2025 Class I recall, endotoxin). NMN reinstated as a supplement Sept 2025 (NDI required).
StatusResearch-use-only — gray market
503A bulksNot on the bulks list
Category 2 (2026)Coenzyme on a separate track (NOT in the peptide reclassification). NAD+ is 503B-INELIGIBLE (GenoGenix warning letter).
PCAC reviewnone scheduled
WADANot listed
03

Evidence — the honest read

Emechanistic / anecdotal

Oral precursors (NMN/NR) reliably raise blood NAD+ (surrogate) but functional benefit unproven; injectable NAD+ is poorly tolerated and not clearly superior. No FDA approval any route.

04

Safety

Contraindications
  • Pregnancy/breastfeedinghard stop
  • Active/late-stage cancer (theoretical fuel; pause before chemo/surgery)
  • Endotoxin/sepsis vulnerability (injectable)
Key interactions
  • Antidiabetics (glucose effects - monitor)
  • Antihypertensives (additive BP - theoretical)
Serious signals
  • 2025 Class I recall of compounded injectable NAD+ (endotoxin -> ER visits)
  • IV 500 mg: ~100% moderate-to-severe acute AEs
  • 503B-ineligible
Monitoring

Glucose with antidiabetics; LFTs with high-dose oral.

06

Sources

01FDA GenoGenix recall; Frontiers in Aging 2026
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: moderate-good